<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383318</url>
  </required_header>
  <id_info>
    <org_study_id>PDX 06-001</org_study_id>
    <nct_id>NCT00383318</nct_id>
  </id_info>
  <brief_title>Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia</brief_title>
  <official_title>Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mednax Center for Research, Education, Quality and Safety</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mednax Center for Research, Education, Quality and Safety</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the demographic, metabolic, and genomic&#xD;
      characteristics of patients who develop severe hyperbilirubinemia to patients who never&#xD;
      developed a significant bilirubin level.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the demographic, metabolic, and genomic&#xD;
      characteristics of patients who develop severe hyperbilirubinemia (serum bilirubin level in&#xD;
      the &quot;high risk zone of greater than the 95th percentile based on the Bhutani nomogram) to&#xD;
      patients who never developed significant hyperbilirubinemia (bilirubin level in &quot;low risk&#xD;
      zone of less than the 40th percentile&quot; on Bhutani nomogram and who did not require any&#xD;
      treatment for hyperbilirubinemia). Our primary goal is to determine if common gene mutations&#xD;
      occur at a greater frequency in patients with severe hyperbilirubinemia than in neonates&#xD;
      without significant hyperbilirubinemia.&#xD;
&#xD;
      The gene mutations we will test for are:&#xD;
&#xD;
        -  Glucose-6-phosphate Dehydrogenase Deficiency [G6PD] gene mutations&#xD;
&#xD;
        -  African A- mutation (G202A;A376G)&#xD;
&#xD;
        -  The common Mediterranean mutation (C563T)&#xD;
&#xD;
        -  Two common Chinese mutations (G1376T and G1388A)&#xD;
&#xD;
        -  UGT1A1 polymorphism. The UGT1A1 gene polymorphisms refer to those genetic defects found&#xD;
           to be associated with Gilbert's Syndrome, including a promoter defect (T-3263G) that&#xD;
           disrupts a transcription regulatory site, the TA repeats promoter polymorphism, and four&#xD;
           mutations within the coding region (G211A, C686A, C1091T, and T1456G).&#xD;
&#xD;
        -  Gene polymorphism for the organic anion transporting protein (OATP-2)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Hyperbilirubinemia</condition>
  <condition>Jaundice</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gene mutation sample</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Case&#xD;
&#xD;
          -  Documentation of informed consent.&#xD;
&#xD;
          -  Gestational age greater than or equal to 37 weeks.&#xD;
&#xD;
          -  Birth weight greater than or equal to 2000 grams.&#xD;
&#xD;
          -  At least one serum bilirubin level that is greater than the 95th percentile (&quot;high&#xD;
             risk zone&quot;) based on the Bhutani nomogram(1), for the case population.&#xD;
&#xD;
          -  Age at enrollment less than 7 days or less than or equal to 168 hours.&#xD;
&#xD;
          -  No major anomalies (chromosomal abnormalities, cyanotic congenital heart disease,&#xD;
             gastroschisis, omphalocele, diaphragmatic hernia, or other major gastrointestinal&#xD;
             anomalies, major neurological injury or anomaly, and multiple congenital anomalies).&#xD;
&#xD;
          -  Ability to follow subjects transferred to another facility for outcome data.&#xD;
&#xD;
        Control&#xD;
&#xD;
          -  Documentation of informed consent.&#xD;
&#xD;
          -  Gestational age greater than or equal to 37 weeks.&#xD;
&#xD;
          -  Birth weight greater than or equal to 2000 grams.&#xD;
&#xD;
          -  At least one estimate of serum bilirubin. Bilirubin level estimated to be less than&#xD;
             the 40th percentile (&quot;low risk zone&quot;) based on the Bhutani nomogram. While a serum&#xD;
             bilirubin in the low risk zone is the preferred method for assessing the bilirubin&#xD;
             level, many pediatricians use transcutaneous measure of bilirubin as a screening tool&#xD;
             for identifying &quot;low risk&quot; patients. For this reason, we will allow controls to be&#xD;
             identified using transcutaneous measurements and collect serum bilirubin levels only&#xD;
             as clinically indicated.&#xD;
&#xD;
          -  Age at enrollment less than 7 days or less than or equal to 168 hours.&#xD;
&#xD;
          -  No major anomalies (chromosomal abnormalities, cyanotic congenital heart disease,&#xD;
             gastroschisis, omphalocele, diaphragmatic hernia or other major gastrointestinal&#xD;
             anomalies, major neurological injury or anomaly, and multiple congenital anomalies).&#xD;
&#xD;
          -  Ability to follow subjects transferred to another facility for outcome data.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Case and Control&#xD;
&#xD;
          -  Gestational age less than 37 weeks.&#xD;
&#xD;
          -  Birth weight less than 2000 grams.&#xD;
&#xD;
          -  Older than 7 days of age or 168 hours.&#xD;
&#xD;
          -  Any major congenital anomalies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reese H Clark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mednax Center for Research, Education, Quality and Safety</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhili Lin, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatrix Screening</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jon Watchko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Greenville Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Watchko JF. Vigintiphobia revisited. Pediatrics. 2005 Jun;115(6):1747-53. Review.</citation>
    <PMID>15930239</PMID>
  </reference>
  <reference>
    <citation>Bhutani VK, Johnson LH, Jeffrey Maisels M, Newman TB, Phibbs C, Stark AR, Yeargin-Allsopp M. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol. 2004 Oct;24(10):650-62. Review.</citation>
    <PMID>15254556</PMID>
  </reference>
  <reference>
    <citation>Johnson LH, Bhutani VK, Brown AK. System-based approach to management of neonatal jaundice and prevention of kernicterus. J Pediatr. 2002 Apr;140(4):396-403.</citation>
    <PMID>12006952</PMID>
  </reference>
  <reference>
    <citation>Ip S, Chung M, Kulig J, O'Brien R, Sege R, Glicken S, Maisels MJ, Lau J; American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. An evidence-based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics. 2004 Jul;114(1):e130-53. Review.</citation>
    <PMID>15231986</PMID>
  </reference>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>October 2, 2006</study_first_submitted>
  <study_first_submitted_qc>October 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2006</study_first_posted>
  <last_update_submitted>January 24, 2008</last_update_submitted>
  <last_update_submitted_qc>January 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2008</last_update_posted>
  <keyword>Neonate</keyword>
  <keyword>Hyperbilirubinemia</keyword>
  <keyword>Jaundice</keyword>
  <keyword>G6PD Deficiency</keyword>
  <keyword>Gilbert's Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Jaundice</mesh_term>
    <mesh_term>Hyperbilirubinemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

